1. South Africa Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
Cilo Cybin Holdings Limited

Cilo Cybin Holdings Limited

JJSE:CCC
150.00
ZAC
0.00
(0.00%)
28.81BMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
0.17
0.1
- -
Basic EPS, GAAP
- -
-0.01
0.01
0.09
-0.83
- -
Free Cash Flow per Basic Share
- -
- -
0.01
0.01
-0.02
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.01
0.73
0.81
0.22
0.22
Tangible Book Value per Share
- -
-0.01
0.73
0.81
0.22
0.22
Basic Weighted Avg Shares
71
71
71
211
288
181
Sales/Revenue/Turnover
- -
- -
- -
35
29
- -
Operating Margin (%)
- -
- -
- -
36.71
-73.04
- -
Depreciation Expense
- -
- -
- -
3
3
- -
Net Income, GAAP
- -
-1
- -
20
-240
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
56.61
-831.99
- -
Working Capital
- -
-1
52
57
58
58
LT Debt
- -
- -
- -
4
4
4
Total Equity
- -
-1
52
57
63
63
Return on Invested Capital (%)
- -
- -
1.91
- -
- -
- -
Return on Capital (%)
- -
- -
1.91
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
36.65
-399.67
- -

Capital Structure

ZAR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
- -
2
1
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
71
288
288
Market Capitalization
285
1,138
288

Working Capital

ZAR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
59
90
62
Cash, Cash Equivalents & STI
- -
58
48
Accounts Receivable, Net
- -
14
2
Inventories
- -
18
12
Total Current Liabilities
2
5
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

ZAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
9.23%
Free Cash Flow
- -
- -
-392.71%
Net Income, GAAP
- -
- -
-1,295.5%
Sales/Revenue/Turnover
- -
- -
-18.65%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ZAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
35
2026
- -
- -
29

Semi-annual Earnings Per Share

ZAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.01
2025
- -
- -
0.09
2026
- -
- -
-0.83

Semi-annual Dividends Per Share

ZAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gabriel Christiaan Theron
Full Time Employees
5
Sector
Finance
Industry
Financial conglomerates
Address
The Point Office Park Centurion GT South Africa 0157
IPO Date
Sep 9, 2022
Website
cilocybin.com
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
Cilo Cybin Holdings Ltd (JSE:CCC) cultivates, manufactures, and sells medical cannabis products worldwide; offers CBD, THC, and THCV distillates, THC and CBD crude oil, CBD, CBG, and CBN isolates, CBD Nano Oil, oils in bottles, cannabis flower, cannabis vapes, topicals, capsules, and device products; provides flower sourcing, formulation, manufacturing, primary and secondary packaging, storage, and exportation services to the cannabis industry; and operates an online shop under the Brand Shop name. The company, founded in 2018 and headquartered in Centurion, South Africa, holds the first medical cannabis cultivation license issued in the country and maintains GACP-accredited indoor cultivation and SAHPRA GMP-accredited manufacturing facilities for vertically integrated operations serving local and international markets, including bulk APIs, oral formulations, inhalation products, and boutique cannabis flower. In December 2024, Cilo Cybin entered a share purchase agreement to acquire 100% of Cilo Cybin Pharmaceutical Proprietary Ltd, its related operating entity, for R845m in shares, a transaction completed in September 2025 that satisfies SPAC viable asset requirements, enhances scalability through state-of-the-art cultivation and drug development capabilities, and positions the group for expansion into psychedelics and domestic South African sales amid evolving regulations.